VIP for Respiratory and Pulmonary Health

Candidate profile

Adults with chronic respiratory inflammation, particularly in the context of:

• Chronic Inflammatory Response Syndrome (CIRS) with documented pulmonary involvement
• Post-mold-exposure respiratory symptoms unresponsive to environmental remediation alone
• Chronic sinusitis with inflammatory markers suggesting persistent mucosal inflammation
• Pulmonary artery hypertension (PAH) — VIP has specific mechanistic relevance here

Not appropriate for: acute respiratory infections, asthma managed with standard therapy, or respiratory symptoms without documented inflammatory or CIRS markers.

Approach

VIP is a 28-amino-acid neuropeptide with potent anti-inflammatory and vasodilatory properties in pulmonary tissue. In the lungs, VIP:

• Relaxes pulmonary vascular smooth muscle (reduces pulmonary arterial pressure)
• Inhibits pro-inflammatory cytokine release from alveolar macrophages
• Stabilizes mast cells (reduces histamine-mediated bronchospasm)
• Promotes regulatory T-cell differentiation in the pulmonary immune compartment
• Protects pulmonary epithelial cells from oxidative stress

The Shoemaker CIRS protocol positions nasal VIP as a late-stage intervention after biotoxin binders, correction of MARCoNS colonization, and normalization of upstream inflammatory markers. VIP addresses the residual pulmonary and vascular inflammation that persists after earlier protocol steps.

Protocol design

Peptide: VIP, 50 mcg per spray

Route: Intranasal (nasal spray formulation)

Dose: 1 spray (50 mcg) into each nostril, 4 times daily (total: 400 mcg/day)

Duration: 30 days initial course, reassess

Prerequisites (Shoemaker protocol): Must have addressed MARCoNS colonization, corrected MSH, and normalized VCS (visual contrast sensitivity) before initiating VIP. Administering VIP to patients with active MARCoNS may worsen the colonization.

Expected timeline

Days 1–7: Some patients report mild nasal congestion improvement and subjective improvement in breathing ease.

Weeks 2–3: Progressive improvement in respiratory symptoms — reduced shortness of breath, improved exercise tolerance, decreased sinus congestion.

Week 4: Reassess inflammatory markers. VIP-responsive patients typically show improvements in TGF-β1, C4a, and VEGF levels.

Ongoing: Some patients require longer courses (2–3 months) for full inflammatory resolution. Others achieve sustained improvement after a single 30-day course.

Monitoring

Biomarkers (baseline and 4 weeks):

• TGF-β1 (transforming growth factor beta-1)
• C4a (complement activation marker)
• VEGF (vascular endothelial growth factor)
• MSH (melanocyte-stimulating hormone) — if CIRS protocol
• MMP-9 (matrix metalloproteinase-9)
• Pulmonary function testing if available (FEV1, FVC, DLCO)

Symptom tracking:

• Dyspnea score (modified Medical Research Council scale)
• Nasal obstruction visual analog scale
• Exercise tolerance (subjective and objective if testing available)
• VCS testing (visual contrast sensitivity) — used in CIRS protocols

Important caveats

• VIP is used primarily within the Shoemaker CIRS protocol framework. Evidence outside this specific context is limited
• The Shoemaker protocol is controversial in mainstream medicine. While some practitioners report significant clinical improvement, large-scale RCTs are lacking
• VIP has a very short half-life (~2 minutes systemically). Intranasal delivery achieves local mucosal concentrations but systemic bioavailability is limited
• VIP for pulmonary arterial hypertension has pilot clinical data showing improved hemodynamics, but this is a serious medical condition requiring specialist management — not self-treatment
• Compounding pharmacy quality for nasal VIP formulations varies. Stability data for VIP in nasal spray is limited